BACKGROUND
The majority of patients with thyroid cancer do very well. Indeed, almost 40% of thyroid cancers are less than 1 cm and have an excellent prognosis. This is because thyroid cancer is usually very slow growing and we have excellent treatment options, usually starting with surgery to remove the cancer. Indeed, small, low-risk thyroid cancers can often be followed by serial ultrasounds before moving to surgery if they grow, a treatment plan called active surveillance.
Percutaneous thermal ablation is a procedure where radiowave-based (radiofrequency ablation, RFA) or microwave-based (microwave ablation, MWA) heat delivered by a needle is used to destroy abnormal thyroid tissue. This has mainly been used to treat benign thyroid nodules, with the advantage being the lack of a scar. Recently, studies have been reported using RFA to treat small thyroid cancers without surgical resection. The 2015 ATA guidelines did not include thermal ablation as an initial management option for thyroid cancer. However, the 2025 guidelines formally recognize ultrasound-guided percutaneous ablation as an alternative to active surveillance or surgical resection for selected patients with small, low-risk thyroid cancer.
THE FULL ARTICLE TITLE
Ringel MD et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 2025;35(8):841-985.
SUMMARY OF THE STUDY
The 2025 ATA thyroid cancer guidelines refer to patients with differentiated thyroid cancer, almost all of which are papillary thyroid carcinoma.
New in these guidelines is the recommendation that ultrasound- guided percutaneous ablation may be considered as an alternative to active surveillance or surgical removal for selected patients with small, low-risk thyroid cancer. This recommendation is conditional and emphasizes shared decision-making.